Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib vs Bevacizumab with FOLFOX/FOLFIRI in 2nd-line mCRC
NCT00615056Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of axitinib in metastatic colorectal cancer (mCRC) (4 arms), sponsored by Pfizer. Primary endpoint: Progression Free Survival at 130 weeks. Started Mar 2008; status: completed.
02
Drugs
axitinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00615056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615056.